Skip to main content
Article thumbnail
Location of Repository

Effective DNA Inhibitors of Cathepsin G by In Vitro Selection

By Barbara Gatto, Elena Vianini, Lorena Lucatello, Claudia Sissi, Danilo Moltrasio, Rodolfo Pescador, Roberto Porta and Manlio Palumbo

Abstract

Cathepsin G (CatG) is a chymotrypsin-like protease released upon degranulation of neutrophils. In several inflammatory and ischaemic diseases the impaired balance between CatG and its physiological inhibitors leads to tissue destruction and platelet aggregation. Inhibitors of CatG are suitable for the treatment of inflammatory diseases and procoagulant conditions. DNA released upon the death of neutrophils at injury sites binds CatG. Moreover, short DNA fragments are more inhibitory than genomic DNA. Defibrotide, a single stranded polydeoxyribonucleotide with antithrombotic effect is also a potent CatG inhibitor. Given the above experimental evidences we employed a selection protocol to assess whether DNA inhibition of CatG may be ascribed to specific sequences present in defibrotide DNA. A Selex protocol was applied to identify the single-stranded DNA sequences exhibiting the highest affinity for CatG, the diversity of a combinatorial pool of oligodeoxyribonucleotides being a good representation of the complexity found in defibrotide. Biophysical and biochemical studies confirmed that the selected sequences bind tightly to the target enzyme and also efficiently inhibit its catalytic activity. Sequence analysis carried out to unveil a motif responsible for CatG recognition showed a recurrence of alternating TG repeats in the selected CatG binders, adopting an extended conformation that grants maximal interaction with the highly charged protein surface. This unprecedented finding is validated by our results showing high affinity and inhibition of CatG by specific DNA sequences of variable length designed to maximally reduce pairing/folding interactions

Topics: Article
Publisher: Molecular Diversity Preservation International (MDPI)
OAI identifier: oai:pubmedcentral.nih.gov:2658781
Provided by: PubMed Central

Suggested articles

Citations

  1. A novel repeated element with Z-DNA-forming potential is widely found in evolutionarily diverse eukaryotic genomes.
  2. (1996). Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation.
  3. (1990). Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy.
  4. (1996). An integrated view of the activities of defibrotide.
  5. (1985). Analytical studies of " mixed sequences" oligodeoxyribonucleotides synthesised by competitive coupling of either methyl- or β- cyanoethyl-N,N diisopropylamino phosphoramidite reagents, including 2'-deoxysine. Nucleic Acids Res.
  6. Characterization of genomic poly(dT-dG).poly(dC-dA) sequences: structure, organization, and conformation.
  7. (1992). Defibrotide inhibits platelet activation by cathepsin G released from stimulated polymorphonuclear leukocytes.
  8. (1995). DNA binds neutrophil elastase and mucus proteinase inhibitor and impairs their functional activity. FEBS Lett.
  9. (2000). DNA strongly impairs the inhibition of cathepsin G by alpha(1)-antichymotrypsin and alpha(1)-proteinase inhibitor.
  10. (2000). Effect of DNase on the activity of neutrophil elastase,
  11. (1992). Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance.
  12. (1998). Effect of polynucleotides on the inhibition of neutrophil elastase by mucus proteinase inhibitor and alpha 1-proteinase inhibitor. Biochemistry
  13. (1989). Elastase and cathepsin G of human monocytes. Quantification of cellular content, release in response of stimuli, and heterogeneity in elastasemediated proteolytic activity.
  14. (1990). Evaluation of elastase and antielastase balance in patients with chronic bronchitis and pulmonary emphysema.
  15. (2006). From proteins to nucleic acid-based drugs: the role of biotech in antiVEGF therapy. Anticancer Agents Med. Chem.
  16. (1991). Genomic structure of murine macrophage inflammatory protein-1 alpha and conservation of potential regulatory sequences with a human homolog,
  17. (2005). Glycosaminoglycan: a candidate to stimulate the repair of chronic wounds.
  18. (1998). Handbook of proteolytic enzymes.
  19. (1994). Heparin protects cathepsin G against inhibition by protein proteinase inhibitors.
  20. (2003). Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin
  21. (1994). Human coagulation factor V is activated to the functional cofactor by elastase and cathepsin G expressed at the monocyte surface.
  22. (1994). Human neutrophyl cathepsin G is a potent platelet activator.
  23. (2004). Immobilized DNA aptamers as target-specific chiral stationary phases for resolution of nucleoside and amino acid derivative enantiomers.
  24. (2000). Improvement of walking distance by defibrotide in patients with intermittent claudication--results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study.
  25. In vitro selection of DNA aptamers that bind LTyrosinamide.
  26. (1992). Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin
  27. (1996). Inhibition of human pancreatic proteinases by mucus proteinase inhibitor, eglin c and
  28. (1999). Inhibition of neutrophil cathepsin G by oxidized mucus proteinase inhibitor. Effect of heparin. Biochemistry
  29. (1989). Inhibition of tissue plasminogen activator inhibitor by defibrotide in atherosclerotic patients.
  30. (2004). Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin
  31. (1980). Kinetic of association of serine proteinases with native and oxidized alpha-(1)-proteinase inhibitor and alpha-(1)-antichymotrypsin.
  32. (2008). Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase.Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site.
  33. (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res.
  34. (2002). Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood
  35. (1998). Multiple sequence alignment with Clustal X. Trends Biochem. Sci.
  36. (1990). Rapid and sensitive sequence comparison with FASTP
  37. (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature
  38. (1990). Systematic evolution of ligands by exponential enrichment:
  39. (1996). The 1.8 A crystal structure of human cathepsin G in complex with Suc-Val-Pro-PheP-(OPh)2: a Janusfaced proteinase with two opposite specificities.
  40. (1997). The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res.
  41. (1988). The effect of eglin C on the function of human neutrophils in vitro.
  42. (1996). The selectivity for K+ versus Na+ in DNA quadruplex is dominated by relative free energies of hydration: a thermodinamic analysis by 1H NMR. Biochemistry

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.